In addition, compared to selective PPAR agonists, targeting two isotypes or pan-PPAR agonists combines the beneficial effects of selective PPAR agonists and improves NAFL/NASH more effectively in multiple ways.138,139. The gene discussed is PPARA; the disease is non-alcoholic fatty liver.